Hunter Syndrome Treatment Market Trends 2021: Comprehensive Insights on Top Key Players, Technological Scope, Revenue Status, Current Trends and Future Investments 2027

SEATTLE, April 01, 2021, (PHARMIWEB) — Global Hunter Syndrome Treatment Market

Hunter syndrome, also termed as Mucopolysaccaridosis type II (MPS II), is a disorder affecting several parts of the body simultaneously. Hunter syndrome is an inherited genetic disorder caused by a certain malfunctioning or missing enzyme in the body. At birth, hunter syndrome patients do not exhibit any features of the disorder; however, changes start becoming noticeable with large round cheeks, an enlarged tongue, swollen lips, and a broad nose. As the disorder advances, individuals need more medical assistance. According to the National Institute of Health 2018 report, Frequency of MPS II is 1 in 100,000 to 1 in 160,000 in males. Hunter syndrome is of two type, severe and mild. These both affect many different tissues and organs. Individuals suffering from severe type condition experience a decline in rapid intellectual function and disease progression. Individuals with the severe case begin to lose basic functional skills between at the ages of 6 and 8. The normal life expectancy of these people is 10 to 20 years. Individuals with mild type also have a shortened lifespan, they live into adulthood and their intelligence is not affected, major causes of death in these individuals is airway obstruction and heart disease. Several diagnostic tests are performed to diagnose hunter syndrome, which includes iduronate-2-sulfatase (I2S) enzyme activity test and a genetic testing. The urine test for GAGs is the most frequently used laboratory screening test for an MPS disorder. Advantages offered by this diagnosis test such as quick results and rapid diagnosis is driving growth of the global hunter syndrome treatment market.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1749

Global Hunter Syndrome Treatment Market Dynamics

As Hunter syndrome has no permanent cure, the treatment mainly focuses on management of indications, signs, and difficulties associated with the disease advancement. Increasing number of population suffering from hunter syndrome has boosted the market growth for Hunter syndrome treatments.  For instance, in 2014, around 970 patients were enrolled in Hunter Outcome Survey (HOC) which increased to 1195 patients in 2017. Moreover, high burden of rare diseases, tax warier, fee reductions and grants, success for the drugs in pipeline with faster market access, financial incentives for orphan drug development to recover R&D costs, favorable regulations for orphan products development are some of the factors expected to fuel market growth over the forecast period. Rising attention of major biopharmaceutical companies on research and development of drugs for treatment of rare diseases is expected to boost demand for mucopolysaccharidosis treatment drugs. Moreover, the number of treatment options currently in pipeline is expected to boost the growth of market during the forecast period.

However, various issues limiting the market growth are heterogeneity of the disease, high cost of treatment, and lack of awareness are some the factors are restraining the growth of the market.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/39wXZ8Z

Global Hunter Syndrome Treatment Market – Regional Landscape

North America accounted for the largest market share in the global hunter syndrome treatment market, due to favorable funding for research and development, better medical facilities, regulations for orphan products development, and rising awareness among the people regarding disrobers and disease. For instance, in 2017, Research funded by the National Institute of Neurological Disorders and Stroke (NINDS) has shown that viral-delivered gene therapy can stop the buildup materials stored in the brain cells and improve memory and learning. In the recent years, health insurance coverage and various reimbursement policies for such costly drugs also influencing pharmaceutical companies to invest in drug development. Moreover, Introduction of particular orphan drug regulations has allowed and increased research and development of various therapies for treatment of several such rare diseases. Developing healthcare infrastructure in Asia Pacific region is providing an opportunity for biopharmaceutical companies to penetrate in this region, which is fueling growth of the market.

Global Hunter Syndrome Treatment Market – Competitive Backdrop

The leading players operating in the global hunter syndrome treatment market include ArmaGen, Inc., BioMarin Pharmaceutical, Inc., Genzyme, Sangamo Therapeutics, a Sanofi Company, and numerous others. These market players are deeply engaged in the development of new technologies and collaborations for retaining a dominant position in the global market. For instance, in 2014, Shire Plc announced collaboration with ArmaGen to develop AGT-182 drug for treatment of hunter syndrome.

To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/1749

Market Taxonomy

On the basis of treatment type:

• Hematopoietic Stem Cell Transplant (HSCT)
• Enzyme Replacement Therapy (ERT)
• Others

By end-user:

• Hospitals
• Clinics
• Specialty Care Unit
• Others

By geography:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Table of Content

Global Hunter Syndrome Treatment Market Research Report
Section 1: Global Hunter Syndrome Treatment Industry Overview
Section 2: Global Economic Impact on Hunter Syndrome Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Hunter Syndrome Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Hunter Syndrome Treatment Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737